---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-021050"
form_type: "8-K"
ticker: null
cik: "0001092662"
company_name: "CHEMBIO DIAGNOSTICS, INC."
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T08:04:12.860317+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Biosynex completes ~$17.2M acquisition of Chembio Diagnostics; Chembio delisted from Nasdaq

## Summary
- Biosynex acquired Chembio for $0.45 per share in cash, transaction value ~$17.2 million.
- Tender offer received ~50.9% of outstanding shares; merger completed April 27, 2023 under Nevada law.
- Chembio becomes wholly-owned indirect subsidiary of Biosynex; stock ceased trading on Nasdaq.
- Credit agreement with Perceptive Credit Holdings terminated; all obligations repaid at closing.
- Larry Abensur and Thierry Paper appointed as officers; all prior directors/officers removed.

## SEC filing metadata
- accession: 0001140361-23-021050
- form_type: 8-K
- cik: 0001092662
- company_name: CHEMBIO DIAGNOSTICS, INC.
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1092662/000114036123021050/0001140361-23-021050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1092662/000114036123021050/brhc20052113_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-021050
- JSON: https://secwatch.observer/filing/0001140361-23-021050.json
- Plain text: https://secwatch.observer/filing/0001140361-23-021050.txt

## Key facts
- Executive change
  Larry Abensur was appointed as other at CHEMBIO DIAGNOSTICS, INC..
  - Action: became
  source text: each officer of Merger Sub immediately prior to the Effective Time became an officer of Chembio effective as of the Effective Time. The officers of Merger Sub immediately prior to the Effective Time were Larry Abensur and Thierry Paper.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1092662/000114036123021050/0001140361-23-021050-index.htm
- Executive change
  Thierry Paper was appointed as other at CHEMBIO DIAGNOSTICS, INC..
  - Action: became
  source text: each officer of Merger Sub immediately prior to the Effective Time became an officer of Chembio effective as of the Effective Time. The officers of Merger Sub immediately prior to the Effective Time were Larry Abensur and Thierry Paper.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1092662/000114036123021050/0001140361-23-021050-index.htm
- Executive change
  Larry Abensur was appointed as Director at CHEMBIO DIAGNOSTICS, INC..
  - Action: became
  - Role: Director
  source text: the sole member of Merger Sub’s board of directors immediately prior to the Effective Time became a member of Chembio’s board of directors effective as of the Effective Time. The member of Merger Sub’s board of directors immediately prior to the Effective Time was Larry Abensur.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1092662/000114036123021050/0001140361-23-021050-index.htm
- M&A Transactions
  CHEMBIO DIAGNOSTICS, INC. underwent a change of control involving Biosynex SA for approximately $17.2 million (closed 2023-04-26).
  - Action: change of control
  - Counterparty: Biosynex SA
  - Consideration: approximately $17.2 million
  - Closing: 2023-04-26
  source text: shares of common stock of Chembio. The consideration was $0.45 per share payable in cash, subject to the terms of the merger agreement, for a transaction value of approximately $17.2 million. The tender offer expired at 6:00 p.m., New York City time, on April 26, 2023. Securities Transfer Corporation, the depositary for the tender offer, has advised Biosynex that
  evidence_url: https://www.sec.gov/Archives/edgar/data/1092662/000114036123021050/0001140361-23-021050-index.htm
- Material Agreements
  CHEMBIO DIAGNOSTICS, INC. terminated Credit Agreement and Guaranty with Perceptive Credit Holdings II, LP valued at All advances and other obligations outstanding under the agreement were repaid. (effective 2023-04-27).
  - Action: termination
  - Agreement: credit facility
  - Counterparty: Perceptive Credit Holdings II, LP
  - Value: All advances and other obligations outstanding under the agreement were repaid.
  - Effective: 2023-04-27
  source text: On April 27, 2023, effective as of the closing of the Merger, Chembio terminated that certain Credit Agreement and Guaranty, dated as of September 3, 2019, by and among Chembio, the Guarantors from time to time party thereto, and Perceptive Credit Holdings II, LP and its successors and assigns party thereto, and concurrently repaid all advances and other obligations outstanding thereunder.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1092662/000114036123021050/0001140361-23-021050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.